SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-05-15
Accession Number: 0001493152-26-023752
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226023752/forms-1a.htm

Chunk 67 of 94
Word Count: 1208
Character Count: 7854

Document Content:

of federal securities law. Our Amended and Restated COI also contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent permitted by the Delaware General Corporation Law. We believe that these provisions will assist us in attracting and retaining qualified individual to serve as directors. Indemnification of Officers and Directors Our Amended and Restated COI contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent permitted by the Delaware General Corporation Law. These provisions may have the practical effect in certain cases of eliminating the ability of stockholders to collect monetary damages from directors. We are also a party to indemnification agreements with each of our directors and officers. We believe that these provisions will assist us in attracting or retaining qualified individuals to serve as our directors and officers. Disclosure of Commission Position on Indemnification for Securities Act Liabilities

Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons
pursuant to the foregoing provisions, we have been informed that in the opinion of the SEC such indemnification is against public policy
as expressed in the Securities Act and is, therefore, unenforceable.

Listing

have applied to have our common stock listed on Nasdaq under the symbol “BVXX”.

History
of Securities Issuances

During
the past three years, we issued securities that were not registered under the Securities Act as set forth below. The following is a summary
of transactions from our inception until the date of this prospectus involving issuance of our securities that were not registered under
the Securities Act. The offers, sales and issuances of the securities described below were exempt from registration either (i) under
Section 4(a)(2) of the Securities Act and the rules and regulations promulgated thereunder in that the transactions were between an issuer
and sophisticated investors, initial purchasers or members of the issuer’s senior executive management and did not involve any
public offering within the meaning of Section 4(a)(2), (ii) under Regulation S promulgated under the Securities Act in that offers, sales
and issuances were not made to persons in the United States and no directed selling efforts were made in the United States, (iii) under
Rule 144A under the Securities Act in that the securities were offered and sold by the initial purchasers to persons reasonably believed
to be qualified institutional buyers, and/or (iv) under Rule 701 promulgated under the Securities Act in that the transactions were under
compensatory benefit plans and contracts relating to compensation.

April
2022 Through August 2022 Series B Preferred Stock Financing

From
April 2022 through August 2022, we issued $10,000,000 of Series B Preferred Stock to accredited investors. As noted below, such
Series B Preferred Stock were later converted into common stock pursuant to the February 2023 recapitalization.

January
2023 Unsecured Convertible Note Financing

January 2023, we issued $3,000,000 in principal amount of its unsecured convertible promissory notes (the “Unsecured Convertible
Notes”) to accredited investors which $3,000,000 principal amount included the exchange of $1,000,000 in principal amount of its
then outstanding unsecured short-term promissory notes for $1,000,000 in principal amount of Unsecured Convertible Notes. The Unsecured
Convertible Notes accrue interest at an annual rate of 10%, had a maturity date of June 30, 2023, and the principal amount automatically
converts into the type of securities issued by us in a subsequent equity financing of at least $10,000,000 in gross proceeds at
the price per share paid by investors in the equity financing. A cash fee of 1.5% of the principal amount of the Unsecured Convertible
Note is also due on the earlier of the conversion of the Unsecured Convertible Note or the maturity date of the Unsecured Convertible
Note. On March 21, 2023, we issued an additional Unsecured Convertible Note in the principal amount of $2,650,000. The aggregate
outstanding amount of $5,650,000 was later converted into 565,000 shares of Series A Preferred Stock in the March 2023 Series A Preferred
Stock Financing.

February
2023 Recapitalization

In February 2023, we completed
a recapitalization pursuant to which all of the Company’s then outstanding Common Stock, Series A Preferred Stock, Series A-1 Preferred
Stock, Series B Preferred Stock were exchanged for new shares of Common Stock of the Company, and all of the Company’s outstanding
Common Stock then underwent a reverse Common Stock split of 1 share of Common Stock share for each 65,500 shares of Common Stock with
any fractional shares of Common Stock existing immediately after the reverse Common Stock split being purchased in cash by the Company
at fair value. Additionally, substantially all of the Company’s then outstanding stock options and warrants were exchanged for
Common Stock.

March
2023 Series A Preferred Stock Financing

On March 30, 2023,
we consummated a Series A Preferred Stock financing (the “March 2023 Series A Preferred Stock Financing”) pursuant to which
we issued $15,650,000 of newly authorized Series A Preferred Stock (which amount included the conversion of the $5,650,000 in principal
amount of our then outstanding Unsecured Convertible Notes) to accredited investors at the initial closing with the potential for issuance
of up to $32,850,000 in additional Series A Preferred Stock in subsequent closings if certain milestones were achieved by us on or before
September 30, 2023. Such milestones were not achieved by us. In connection with the March 2023 Series A Preferred Stock Financing, we
amended and restated our then existing Second Amended and Restated Certificate of Incorporation to read as set forth in its Third Amended
and Restated Certificate of Incorporation which amended and restated certificate provided for an immediate forward Common Stock split
of 176.582 shares of Common Stock for each 1 share of outstanding Common Stock and set forth the rights, preferences, and privileges
of the newly authorized Series A Preferred Stock. Additionally, as part of the March 2023 Series A Preferred Stock Financing, we entered
into an Investors’ Rights Agreement, a Right of First Refusal and Co-Sale Agreement, and a Voting Agreement with the holders of
our Series A Preferred Stock and certain holders of our Common Stock. The Right of First Refusal and Co-Sale Agreement and the Voting
Agreement automatically terminate immediately prior to the closing of this offering. Subsequent to the closing of the March 2023 Series
A Preferred Stock Financing, we filed two amendments to its Third Amended and Restated Certificate of Incorporation which amendments
amended, reduced or eliminated several rights of the Series A Preferred Stock, increased the authorized amount of Common Stock and Preferred
Stock, and designated some of the authorized Preferred Stock as Blank Check Preferred Stock. Upon the closing of this offering (assuming
gross proceeds of $7,500,000 to us in this offering), the Series A Preferred Stock is subject to mandatory conversion such that each
outstanding share of Series A Preferred Stock will automatically convert into shares of Common Stock at a conversion rate equal to the
greater of (A) the then effective conversion rate as calculated pursuant to Section 5 of the Third Amended and Restated Certificate
of Incorporation, as amended or (B) the original issue price of the Series A Preferred Stock divided by the price per share of the Common
Stock issued in this offering.

March
2024 Through August 2024 Series A Secured Convertible Note Financing